Published in Immunotherapy Weekly, January 11th, 2012
"In their paper, Chang and colleagues demonstrate the effectiveness of a Bruton tyrosine kinase (Btk) inhibitor in two models of RA. Btk inhibition impacts several pathways affecting both B-cell and macrophage activation, making it a promising target in RA," wrote E.M. Ruderman and colleagues, Northwestern University.
The researchers concluded: "However, other kinase inhibitors have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly